A Phase 1/2 trial of Moderna’s mRNA-1083 found strong immune responses against both viruses, similar to existing vaccines. Most side effects were mild.
A Phase 1/2 trial of Moderna’s mRNA-1083 found strong immune responses against both viruses, similar to existing vaccines. Most side effects were mild.